Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 13/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 5/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 5/20 | 0.55 |
| ▸ | F2 | P00734 | 3/20 | 0.55 |
| ▸ | PLG | P00747 | 2/20 | 0.55 |
| ▸ | C1S | P09871 | 3/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9608570 | 0.98 | PRSS1 (0.53) | PRSS1PRSS2PRSS3F2PLG | |
| Isopropyl Alcohol SCHEMBL28326201 | 0.92 | PRSS1 (0.47) | PRSS1PRSS2PRSS3F2PLG | |
| Hydrochloric Acid SCHEMBL28325039 | 0.84 | GSK3B (0.48) | PRSS1PRSS2PRSS3F2PLG | |
| Phenyl Ethanol SCHEMBL28326106 | 0.84 | PRSS1 (0.46) | PRSS1PRSS2PRSS3F2PLG | |
| Hydrochloric Acid SCHEMBL28326094 | 0.83 | PRSS1 (0.40) | PRSS1PRSS2PRSS3F2PLG | |
| Benzamidine SCHEMBL27541129 | 0.81 | PRSS1 (0.53) | PRSS1PRSS2PRSS3F2PLG | |
| Hydrochloric Acid SCHEMBL4380330 | 0.81 | GSK3B (0.59) | PRSS1RECQLGSK3BBLM | |
| Hydrochloric Acid SCHEMBL28877632 | 0.81 | S1PR3 (0.43) | PRSS1PRSS2PRSS3F2PLG | |
| Benzamidine SCHEMBL6823484 | 0.80 | PRSS1 (0.68) | PRSS1PRSS2PRSS3F2PLG | |
| SCHEMBL26050098 | 0.79 | WDR5 (0.56) | PRSS1PRSS2PRSS3F2PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114853681-A | Preparation method of pyrimidine heterocyclic guanyl formate compound | 南京工业大学 | 2022-08-05 | — | — | CN | claimed |
| CN-117736120-A | Beta-fluoroalkyl-beta-amino vinyl ketone compound, and preparation method and application thereof | 南京工业大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-115925583-A | Preparation method of beta-fluoroalkyl-beta-aminovinyl ketone compound | 南京工业大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-114853681-A | Preparation method of pyrimidine heterocyclic guanyl formate compound | 南京工业大学 | 2022-08-05 | — | — | CN | disclosed |
| EP-2261279-A1 | Triazine derivative, ultraviolet absorber composition and resin composition stabilized with the absorber composition | Fujifilm Corporation (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20100311877-A1 | NOVEL TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION | FUJIFILM CORPORATION (JP) | 2010-12-09 | — | — | US | disclosed |
| US-7115602-B2 | Heterocycles 3 | BAYER AKTIENGESELLSCHAFT (DE) | 2006-10-03 | — | — | US | disclosed |
| US-7087605-B2 | 5-Ethyl-imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-08 | — | — | US | disclosed |
| US-7074790-B2 | 5-ethylimidarotriazones | BAYER HEALTHCARE AG (DE) | 2006-07-11 | — | — | US | disclosed |
| US-20060040942-A1 | 5-ethylimidarotriazones | BAYER HEALTHCARE AG (DE) | 2006-02-23 | — | — | US | disclosed |
| EP-1399447-A1 | IMIDAZOTRIAZINONES DERIVATIVES AND THEIR USE AGAINST INFLAMMATORY PROCESSES AND/OR IMMUNE DISEASES | Bayer HealthCare AG (DE) | 2004-03-24 | — | — | EP | disclosed |
| EP-1397363-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | Bayer HealthCare AG (DE) | 2004-03-17 | — | — | EP | disclosed |
| WO-2003097645-A1 | 5-ETHYLIMIDAROTRIAZONES | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
| EP-0799209-B1 | SULFONAMIDES | HOFFMANN LA ROCHE (CH) | 2003-08-06 | — | — | EP | disclosed |
| US-20030139415-A1 | Novel heterocycles 3 | BAYER HEALTHCARE AKTIENGESELLSCHAFT (DE) | 2003-07-24 | — | — | US | disclosed |
| WO-2002098879-A1 | IMIDAZOTRIAZINONES DERIVATIVES AND THEIR USE AGAINST INFLAMMATORY PROCESSES AND/OR IMMUNE DISEASES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002098880-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
| US-6004965-A | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0799209-A1 | NOVEL SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019459-A1 | NOVEL SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139415-A1 | Novel heterocycles 3 | NFATC1, NOD2, NFKBIA | PRSS1 1287/4885PRSS2 1634/4885PRSS3 1044/4885 |
| US-20060040942-A1 | 5-ethylimidarotriazones | IL5, EPX, NFATC1 | PRSS1 420/4885PRSS2 546/4885PRSS3 372/4885 |
| US-20100311877-A1 | NOVEL TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION | AVPR1B, H1-0, H1-2 | PRSS1 987/4885PRSS2 922/4885PRSS3 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.